Aratana Therapeutics (NASDAQ:PETX) was upgraded by investment analysts at CL King from a “neutral” rating to a “buy” rating in a research report issued on Monday, Marketbeat reports. The brokerage currently has a $8.00 target price on the biopharmaceutical company’s stock. CL King’s target price indicates a potential upside of 81.00% from the company’s previous close. The analysts noted that the move was a valuation call.
PETX has been the topic of several other research reports. Jefferies Group set a $9.00 price target on Aratana Therapeutics and gave the company a “buy” rating in a research note on Thursday, November 16th. Stifel Nicolaus reiterated a “hold” rating and set a $6.00 price target on shares of Aratana Therapeutics in a research note on Monday, December 18th. ValuEngine downgraded Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. Zacks Investment Research upgraded Aratana Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, March 7th. Finally, HC Wainwright started coverage on Aratana Therapeutics in a research note on Friday, November 17th. They set a “buy” rating and a $10.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. Aratana Therapeutics has an average rating of “Hold” and a consensus target price of $8.46.
Aratana Therapeutics (NASDAQ PETX) traded up $0.16 during trading on Monday, reaching $4.42. The company’s stock had a trading volume of 503,048 shares, compared to its average volume of 401,723. The company has a current ratio of 3.42, a quick ratio of 3.08 and a debt-to-equity ratio of 0.26. The stock has a market cap of $183.18, a P/E ratio of -3.05 and a beta of 3.13. Aratana Therapeutics has a twelve month low of $3.71 and a twelve month high of $7.67.
Several hedge funds have recently modified their holdings of the company. MetLife Investment Advisors LLC acquired a new position in shares of Aratana Therapeutics in the 4th quarter valued at about $110,000. Millennium Management LLC acquired a new position in shares of Aratana Therapeutics in the 4th quarter valued at about $3,267,000. Ellington Management Group LLC acquired a new position in shares of Aratana Therapeutics in the 4th quarter valued at about $304,000. Goldman Sachs Group Inc. lifted its holdings in shares of Aratana Therapeutics by 35.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 68,039 shares of the biopharmaceutical company’s stock valued at $358,000 after buying an additional 17,677 shares during the period. Finally, Deutsche Bank AG lifted its holdings in shares of Aratana Therapeutics by 11.2% in the 4th quarter. Deutsche Bank AG now owns 468,114 shares of the biopharmaceutical company’s stock valued at $2,461,000 after buying an additional 47,178 shares during the period. 71.07% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Aratana Therapeutics (PETX) Upgraded by CL King to Buy” was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/03/12/aratana-therapeutics-petx-upgraded-by-cl-king-to-buy.html.
About Aratana Therapeutics
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.